Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib vs Investigator's Choice in R/R CLL
NCT02970318Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Feb 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free Survival Per Independent Review Committee (IRC) Assessment up to 22 months. Started Feb 2017; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02970318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970318.